NextCure, Inc. — 2021 Form 10-K Summary
Business context and reporting period. This annual report covers the fiscal year ended December 31, 2021. NextCure is a clinical-stage biopharmaceutical company developing immunomedicines for cancer and other immune-related diseases using its FIND-IO discovery platform. It has no approved products and has never generated product-sale revenue.
Key financial metrics
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | $0 | $22.4 million |
| Research and development expense | $50.2 million | $46.6 million |
| General and administrative expense | $20.6 million | $17.0 million |
| Operating loss | $70.8 million | $41.2 million |
| Net loss | $69.4 million | $36.6 million |
| Basic and diluted loss per share | $2.51 | $1.33 |
| Net cash used in operating activities | $57.2 million | $45.0 million |
Margins and profitability: The company remained loss-making, with no meaningful revenue-based margin to report. The 2020 revenue was a one-time $22.4 million recognition of deferred revenue after Lilly terminated its collaboration; it was not recurring product revenue.
Liquidity and balance sheet: At year-end, cash and cash equivalents were $12.3 million and marketable securities were $207.3 million, or $219.6 million combined excluding restricted cash. Current assets were $227.8 million, total assets $242.4 million, total liabilities $9.0 million, and stockholders’ equity $233.4 million. The $5.0 million term loan was fully repaid in August 2021; no term-loan balance remained at year-end.
Cash flow and other items: Investing activities provided $36.6 million, primarily from net maturities of marketable securities, partly offset by $2.4 million of property and equipment purchases. Financing activities used $3.3 million, primarily for term-loan payments. Comprehensive loss was $70.8 million, including a $1.4 million unrealized loss on marketable securities.
Material changes versus 2020
- Net loss widened to $69.4 million from $36.6 million, while revenue fell to zero from $22.4 million following the one-time Lilly-related revenue recognition in 2020.
- R&D expense increased $3.6 million, mainly from clinical and personnel costs; G&A expense increased $3.5 million, primarily from personnel-related costs.
- Operating cash use increased to $57.2 million from $45.0 million. The prior-year figure included the $22.4 million deferred-revenue recognition, which reduced 2020 net loss but did not represent product sales.
- Other income, net declined to $1.4 million from $4.6 million, reflecting lower investment balances and interest rates. The company repaid its remaining term-loan principal during 2021.
Outlook, commentary and risks
- Management expects existing cash, cash equivalents and marketable securities to fund planned operations into the first quarter of 2024. This estimate depends on assumptions that may prove incorrect; the company expects substantial future spending and will require additional capital.
- NC318 remained in Phase 1/2 development. The company reported early evidence of possible clinical benefit in some patients and generally mild or moderate treatment-related adverse events in Phase 2. It changed the Phase 2 regimen to 800 mg weekly to increase drug exposure and expected further Phase 2 data in the fourth quarter of 2022. Yale began a Phase 2 NC318-plus-pembrolizumab study in NSCLC; initial data were anticipated in the second half of 2022.
- NC410 was in Phase 1/2 testing; interim dose-escalation data indicated apparent tolerability and immune modulation. Further Phase 1 data were expected in the second half of 2022.
- NC762 entered a Phase 1/2 trial in July 2021; initial Phase 1 data were expected in the second half of 2022. NC525 remained preclinical, with an IND submission planned for the fourth quarter of 2022.
- Key risks include clinical and regulatory uncertainty, small early-trial populations, patient-enrollment and COVID-19 disruption, manufacturing scale-up and supply dependence, competition, and the need for additional financing. The company also reported securities-related and derivative litigation, plus a trade-secret lawsuit; it could not estimate reasonably possible losses for these cases.
- The Lilly collaboration had ended in March 2020, eliminating future support payments and potential milestone or royalty income under that agreement. The Yale sponsored research agreement expired December 31, 2021 and was not expected to be renewed.
Important facts for investors to verify
- Whether cash and marketable securities, actual spending, and financing plans support the stated runway into Q1 2024.
- Updated NC318 results, including outcomes after the revised dose and S15-positive patient selection, and the NC318/pembrolizumab study timeline.
- Progress, safety findings and data timelines for NC410 and NC762, and whether NC525 meets its planned IND timeline.
- Whether clinical-trial, manufacturing, or enrollment costs materially exceed management’s expectations, including effects from COVID-19 or supply constraints.
- Developments in the disclosed litigation and any resulting financial, operational, or intellectual-property consequences.